Vicor Technologies Announces Exclusive Distribution Agreement for its PD2i® Products in Israel

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company has entered into an agreement with Hadar Training and Medical Services to serve as its exclusive agent for the marketing and sale of its PD2i Analyzer™, PD2i CA™ (Cardiac Analyzer) and PD2i VS ™ (Vital Sign) in Israel and Palestine.  Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software.  Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

  • The PD2i Analyzer™ measures heart trate variability in patients at rest, and in response to controlled exercise and paced respiration.
  • The PD2i CA™ (Cardiac Analyzer) identifies cardiovascular disease patients at risk of death from arrhythmia or pump failure.
  • The PD2i VS™ (Vital Sign) quickly evaluates critically-injured soldiers and civilians to improve triage and survivability. The PD2i VS™ is in ongoing trials in collaboration with the U.S. Army Institute of Surgical Research.

Vicor has 510(k) marketing clearance from the FDA for the PD2i Analyzer™.

The comments are closed.